Anupam Dalal

Anupam is a board member of Aerpio Therapeutics and Akebia Therapeutics. He led Kearny's investment in Nextwave Pharmaceuticals. At Flagship, he was a board member with Resolvyx Pharmaceuticals and Pervasis (acquired by Shire) and an observer at CGI Pharmaceuticals (acquired by Gilead), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Acceleron Pharma. Prior to Flagship Ventures, Anupam received his M.D. from the University of California, San Francisco, with honors. Anupam was Resident in Surgery at Brigham and Women's Hospital / Harvard Medical School. He received an MBA from Harvard Business School, with Distinction, and a BA (Phi Beta Kappa) in Economics summa cum laude from the University of California at Berkeley.